Zimmer Biomet Holdings Inc
Research Zimmer Biomet Holdings Inc (ZBH) on Bullrun: valuation model: 0.6% undervalued, market cap USD 17.65B, P/E 23.7, dividend yield 1.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZBH
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal0.6% undervalued
- Market capUSD 17.65B
- P/E23.7
- Dividend yield1.1%
- Financial periodFY2025
- RevenueUSD 8.23B
- Revenue growth7.2%
- Net incomeUSD 705.10M
- Free cash flowUSD 1.47B
- Gross margin69.7%
Valuation Snapshot
Bullrun's latest valuation model marks Zimmer Biomet Holdings Inc as 0.6% undervalued; latest market cap is USD 17.65B; P/E is 23.7; dividend yield is 1.1%.
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder;
Frequently asked questions
Is Zimmer Biomet Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks Zimmer Biomet Holdings Inc as 0.6% undervalued.
What is Zimmer Biomet Holdings Inc's market cap?
Zimmer Biomet Holdings Inc's market capitalization is USD 17.65B.
What is Zimmer Biomet Holdings Inc's P/E ratio?
Zimmer Biomet Holdings Inc's price-to-earnings (P/E) ratio is 23.7.
Does Zimmer Biomet Holdings Inc pay a dividend?
Zimmer Biomet Holdings Inc has a dividend yield of 1.1%.
What does Zimmer Biomet Holdings Inc do?
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.